Medical cannabis is a topic of growing interest for patients, carers, and healthcare professionals in the UK. However, the terminology around cannabis-based medicines can be confusing, especially when you hear terms like “unlicensed” used to describe these products. This article breaks down what "unlicensed" medical cannabis means, explains how it fits within UK law, and clarifies the roles of NHS and private clinics in prescribing these treatments.
Understanding Medical Cannabis: Plain English Definitions
Before we dive into unlicensed medicines, let's first define some key terms.
What is Medical Cannabis?
Medical cannabis refers to cannabis or cannabis-derived products that are used to treat certain health conditions. These products might include oils, capsules, sprays, or other forms containing chemicals called cannabinoids. The two most well-known cannabinoids are:
- THC (tetrahydrocannabinol): The compound that causes a "high" sensation. CBD (cannabidiol): A compound thought to have medicinal benefits without causing intoxication.
In the UK, medical cannabis products must be prescribed by a doctor and are intended to help with conditions such as severe epilepsy, multiple sclerosis, chronic pain, or nausea caused by chemotherapy—though the list of accepted uses is limited and evolving.
What Does "Unlicensed" Medicine Mean?
An unlicensed medicine is a medicine that does not have a licence (or approval) from the Medicines and Healthcare products Regulatory Agency ( MHRA) to be sold or marketed for a specific condition in the UK. In contrast, a licensed medicine has undergone rigorous testing and regulatory checks for safety, efficacy, and quality for each intended use.
Here is the bit people miss: Many medicines prescribed by NHS doctors are licensed, but sometimes doctors use their professional judgement to prescribe unlicensed medicines when no licensed option is available, or when a patient’s needs are very specific.
Unlicensed Cannabis-Based Products in the UK: What You Need to Know
Medical cannabis products available in the UK mostly fall into the “unlicensed” category.
The availability and licensing -> It’s important to note that only one cannabis-based medicine, Sativex (also called nabiximols), is licensed and available on the NHS for use in multiple sclerosis spasticity. All other medical cannabis products prescribed in the UK are unlicensed.
What Does This Mean for Patients?
If your doctor recommends medical cannabis that is “unlicensed,” it means:
- There is no MHRA licence specifically for that product for your condition. It has not gone through the standard regulatory approval for that use. Your doctor is using specialist clinical judgement to decide that the benefits outweigh risks based on scientific evidence and patient need. There is less standardised information on dosing, side-effects, or long-term safety compared to licensed medicines. The medicine will often be imported specially and can be more expensive.
The UK Legal and Regulatory Background
Medical cannabis was rescheduled in November 2018 in the UK, meaning specialist doctors in the NHS and private sector can legally prescribe cannabis-based products for medicinal use.
The legal framework includes:
- Misuse of Drugs Regulations 2001: Redefined to allow prescriptions of cannabis-based medicines for medical use. NHS England guidance: Specialist-led prescribing encouraged but tightly controlled. Medicines and Healthcare products Regulatory Agency (MHRA): Maintains the licensing and regulation of medicines.
Here is the bit people miss: The law allows prescriptions, but does not compel NHS services to provide medical cannabis. That means NHS access is limited and unpredictable.
NHS Reality vs Private Specialist Clinics
medical cannabis for chronic pain UKWhen it comes to prescribing medical cannabis in the UK, the healthcare setting matters a lot.
NHS Pathway
On the NHS:
- Medical cannabis can only be prescribed by specialist doctors (not GPs). It is reserved for exceptional cases, mostly where other treatment options have failed. Clinicians use strict criteria and existing evidence before considering unlicensed cannabis-based products. Prescribing unlicensed cannabis outside licensed indications is very rare.
Because of these restrictions, many patients find NHS access difficult to get. Waiting lists are long and local policy may not be supportive.
Private Specialist Clinics
Private clinics offer an alternative pathway:
- Private specialists may be more willing to prescribe unlicensed cannabis-based products after an assessment. Appointments and prescribing decisions can be quicker but come at a significant financial cost to the patient. Private doctors also rely on specialist judgement but may have broader discretion given the absence of NHS funding rules.
Here is the bit people miss: Choosing private prescribing means paying for consultations, follow-ups, and the medicine itself, which often is not available on NHS prescription.
Specialist Judgement and Safety Considerations
Prescribing unlicensed cannabis-based medicines depends heavily on a specialist doctor’s clinical judgement. What does this mean?
- Assessing the evidence: The specialist reviews current research, patient history, and the potential benefits and risks specific to the patient. Monitoring effects: Close follow-up is required to check efficacy and side effects. Individualised treatment: Doses and formulations may be tailored uniquely, unlike standard licensed meds with fixed protocols.
Doctors must balance scientific evidence, patient needs, and legal guidance to responsibly prescribe these medicines.
Why Is Specialist Judgement Crucial for Unlicensed Medicine Prescription in the UK?
Unlike licensed medicines, unlicensed products do not have the same level of regulatory approval, so the doctor’s expertise ensures patient safety is prioritised. This responsibility includes:
Confirming no suitable licensed alternative exists. Explaining the risks, benefits, and limitations transparently to the patient. Documenting the rationale carefully. Ensuring the product is obtained from a reputable supplier meeting UK standards.Key Takeaways
- “Unlicensed” medical cannabis means the product lacks formal UK regulatory approval for the prescribed use, but can still be legally prescribed by specialists. NHS prescribing of medical cannabis, especially unlicensed products, is tightly controlled and limited to specialist clinics for specific cases. Private clinics offer more access to unlicensed cannabis-based medicines but at higher personal cost. Specialist clinical judgement is at the heart of prescribing unlicensed cannabis products safely and appropriately. Patients should have clear, honest conversations with their doctors about benefits, risks, and licensing status before starting treatment.
Further Resources
- NHS - Medical Cannabis Information UK Government - Medical Cannabis Access Guidance NICE Guidance on Cannabis-Based Medicinal Products